Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
About Citius Pharmaceuticals, Inc.
- NASDAQ: $CTXR
- Notified: $1.30
- 09:01 EDT
